Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Ruzasvir in Hepatitis C
NCT02076100Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of ruzasvir in hepatitis C (HCV) (3 arms), sponsored by Merck & Co. Primary endpoints: Maximum log10 HCV Ribonucleic Acid (RNA) Change From Baseline at Day 5, Number of Participants Who Experienced One or More Adverse Events (AEs) at Day 61 and 1 more. Started Mar 2014; status: completed.
02
Drugs
ruzasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02076100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02076100.